sera prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications. sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. the company has assembled a strong management team and board of directors with significant clinical development and women’s healthcare diagnostic experience. the company is supported by a strong group of investors, including the bill & melinda gates foundation, chione, ltd, domain associates, interwest partners, catalyst health ventures, upstart life sciences capital, and osage university partners. the company is working with the bill & melinda gates foundation to translate its discoveries and develop technologies to benefit women and infants in underserved countries worldwide. sera prognostics is located in salt lake city, utah. sera launched its first diagnos
Company profile
Ticker
SERA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
261911522
SERA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Sera Prognostics Reports Fourth Quarter 2023 Financial Results
20 Mar 24
8-K
Entry into a Material Definitive Agreement
12 Dec 23
8-K
Sera Prognostics Announces Primary Endpoint Criteria Met
6 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Sera Prognostics Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Regulation FD Disclosure
25 Sep 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Sera Prognostics Reports Second Quarter 2023 Financial Results
9 Aug 23
Transcripts
SERA
Earnings call transcript
2023 Q3
8 Nov 23
SERA
Earnings call transcript
2023 Q2
9 Aug 23
SERA
Earnings call transcript
2023 Q1
10 May 23
SERA
Earnings call transcript
2022 Q4
22 Mar 23
SERA
Earnings call transcript
2022 Q3
13 Nov 22
SERA
Earnings call transcript
2022 Q2
10 Aug 22
SERA
Earnings call transcript
2022 Q1
15 May 22
SERA
Earnings call transcript
2021 Q4
30 Mar 22
Latest ownership filings
SC 13G
RA CAPITAL MANAGEMENT, L.P.
1 Apr 24
4
John J. Boniface
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Zhenya Lindgardt
26 Mar 24
4
Austin Aerts
26 Mar 24
4
John J. Boniface
26 Mar 24
4
John J. Boniface
26 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.66 mm | 9.66 mm | 9.66 mm | 9.66 mm | 9.66 mm | 9.66 mm |
Cash burn (monthly) | 7.54 mm | 2.43 mm | 2.73 mm | 3.45 mm | 2.53 mm | 2.31 mm |
Cash used (since last report) | 51.22 mm | 16.50 mm | 18.52 mm | 23.42 mm | 17.19 mm | 15.65 mm |
Cash remaining | -41.56 mm | -6.84 mm | -8.87 mm | -13.77 mm | -7.53 mm | -6.00 mm |
Runway (months of cash) | -5.5 | -2.8 | -3.3 | -4.0 | -3.0 | -2.6 |
Institutional ownership, Q2 2023
71.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 3 |
Closed positions | 7 |
Increased positions | 3 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 29.71 bn |
Total shares | 23.08 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
ELV Elevance Health | 3.20 mm | $21.99 mm |
Interwest Partners X | 2.54 mm | $0.00 |
Domain Partners VIII | 2.52 mm | $17.34 mm |
Interwest Venture Management | 2.42 mm | $7.96 bn |
Chione | 1.98 mm | $23.57 mm |
Yair Chaim Schindel | 1.92 mm | $0.00 |
Vivo Capital | 1.86 mm | $6.12 bn |
Vivo Capital IX | 1.86 mm | $18.28 mm |
Baker Bros. Advisors | 1.78 mm | $5.86 bn |
Vanguard | 773.43 k | $2.55 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | John J. Boniface | Class A Common Stock | Sell | Dispose S | No | Yes | 9.04 | 24,474 | 221.24 k | 139,771 |
28 Mar 24 | John J. Boniface | Class A Common Stock | Option exercise | Acquire M | No | No | 0.91 | 24,474 | 22.27 k | 164,245 |
28 Mar 24 | John J. Boniface | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 0.91 | 24,474 | 22.27 k | 0 |
27 Mar 24 | John J. Boniface | Class A Common Stock | Sell | Dispose S | No | Yes | 9.62 | 48,909 | 470.50 k | 139,771 |
27 Mar 24 | John J. Boniface | Class A Common Stock | Option exercise | Acquire M | No | No | 0.91 | 48,909 | 44.51 k | 188,680 |
27 Mar 24 | John J. Boniface | Class A Common Stock | Sell | Dispose S | No | Yes | 9.62 | 3,753 | 36.10 k | 139,771 |
27 Mar 24 | John J. Boniface | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 0.91 | 48,909 | 44.51 k | 24,474 |
26 Mar 24 | John J. Boniface | Class A Common Stock | Sell | Dispose S | No | Yes | 9.55 | 21,438 | 204.73 k | 143,524 |
26 Mar 24 | Austin Aerts | Class A Common Stock | Sell | Dispose S | No | No | 9.37 | 8,092 | 75.82 k | 322,488 |
26 Mar 24 | Zhenya Lindgardt | Class A Common Stock | Sell | Dispose S | No | No | 9.37 | 38,899 | 364.48 k | 908,104 |
News
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
25 Mar 24
Sera Prognostics: Q4 Earnings Insights
20 Mar 24
Sera Prognostics Q4 2023 GAAP EPS $(0.25) Beats $(0.26) Estimate, Sales $41.000K Miss $50.000K Estimate
20 Mar 24
Earnings Scheduled For March 20, 2024
20 Mar 24